Table 2.
Clinical Details of Patients with Breast Cancer.
| Factor | All Cancer Patients | |
| n | % | |
| n | 160 | 100 |
| Route of diagnosis | ||
| Screening | 73 | 46 |
| Symptom | 97 | 54 |
| Family history | 50 | 31 |
| Multifocal disease | 18 | 11 |
| Tumor type | ||
| DCIS/LCIS | 6 | 4 |
| IDC | 118 | 74 |
| ILC | 19 | 12 |
| Special type | 17 | 10 |
| Tumor size | ||
| T1 (<2 cm) | 83 | 52 |
| T2 (>2 cm, <5 cm) | 57 | 35 |
| T3/T4 (>5 cm, skin, chest) | 20 | 13 |
| Vascular invasion | ||
| +ve | 37 | 23 |
| -ve | 98 | 61 |
| Unknown | 25 | 16 |
| Histologic grade | ||
| Low | 37 | 23 |
| Moderate | 76 | 48 |
| High | 47 | 29 |
| ER/PR status | ||
| ER+ | 127 | 79 |
| ER/PR- | 24 | 15 |
| Unknown | 9 | 6 |
| Nodal status | ||
| -ve | 86 | 54 |
| 1–3 nodes + ve | 39 | 24 |
| >4 nodes + ve | 22 | 14 |
| Unknown | 13 | 8 |
| Her-2 | ||
| +ve | 16 | 10 |
| -ve | 31 | 19 |
| Unknown | 113 | 71 |
| Metastatic | 9 | 6 |
DC indicates invasive ductal carcinoma; DCIS, ductal carcinoma in situ; ER, estrogen receptor; ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; PR, progesterone receptor.